Nisa Investment Advisors LLC Sells 4,700 Shares of Hologic, Inc. (NASDAQ:HOLX)

Nisa Investment Advisors LLC decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 9.6% during the 3rd quarter, Holdings Channel reports. The firm owned 44,056 shares of the medical equipment provider’s stock after selling 4,700 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Hologic were worth $3,589,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its stake in Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after buying an additional 2,753,016 shares during the last quarter. Swedbank AB acquired a new stake in Hologic during the 1st quarter valued at $120,827,000. Black Creek Investment Management Inc. increased its holdings in Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Mackenzie Financial Corp raised its position in Hologic by 1,023.3% in the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock valued at $66,506,000 after purchasing an additional 815,960 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Hologic during the second quarter worth $39,427,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on HOLX. Leerink Partners cut their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Royal Bank of Canada reissued a “sector perform” rating and set a $82.00 price target on shares of Hologic in a research note on Friday, August 16th. Evercore ISI boosted their price objective on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Finally, Stephens reiterated an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.50.

Hologic Stock Up 1.8 %

NASDAQ:HOLX opened at $82.33 on Friday. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 12-month low of $66.53 and a 12-month high of $84.67. The stock’s fifty day simple moving average is $80.99 and its 200-day simple moving average is $77.98. The firm has a market capitalization of $19.12 billion, a P/E ratio of 28.00, a P/E/G ratio of 2.94 and a beta of 0.98.

Insiders Place Their Bets

In other news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.